Fighting Cancer in Coronavirus Disease Era: Organization of Work in Medical Oncology Departments in Emilia Romagna Region of Italy
Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Davide Tassinari(University of Bologna), Giuseppe Longo(University of Modena and Reggio Emilia), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), A Maestri(Santa Maria Nuova Hospital), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Vincenzo Di Nunno(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Luigi Cavanna(University of Pavia), Giovanni Luca Frassineti, Federico Cappuzzo(Ospedale di Livorno), Francesco Leonardi(University of Parma), Fabrizio Artioli(Roche (Switzerland))
Cited by 16
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
|JNCI Journal of the National Cancer Institute|2005|1.6k